AstraZeneca, Genertec Meheco ink deal for COVID therapy Evusheld in China
Fotonen         

AstraZeneca (NASDAQ:AZN) signed an agreement with China-basedÂ Genertec Meheco for its COVID-19 antibody therapy Evusheld, Reuters reported.
Genertec Meheco, a subsidiary of Shanghai-listed China Meheco Group, would be responsible for importing and distributing Evusheld in mainland China, upon approval or emergency use authorization in the Asian country, the report added.